| Karen Lee Pearson, PA-C | |
|
104 West 2nd Street, Alcester, SD 57001-0468 | |
| (605) 934-2122 | |
| Not Available |
| Full Name | Karen Lee Pearson |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 27 Years |
| Location | 104 West 2nd Street, Alcester, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861480501 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 0391 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Compassionate Care Hospice | Sioux falls, SD | Hospice |
| Hawarden Regional Healthcare | Hawarden, IA | Hospital |
| Sanford Canton-inwood Medical Center - Cah | Canton, SD | Hospital |
| Alcester Care And Rehab Center, Inc | Alcester, SD | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Horizon Health Care Inc | 8921997933 | 54 |
News Archive
Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Researchers at the University of Pennsylvania School of Medicine are now studying an investigational treatment that may offer a significant new, minimally-invasive option for those suffering from advanced widespread emphysema.
Compared to patients receiving care from primary care physicians, asthma patients who are under the care of an allergist report fewer asthma control problems and less sever asthma symptoms, according to new research in the December 2005 Journal of Allergy & Clinical Immunology (JACI).
The American College of Chest Physicians and Thomas Jefferson University are launching a free online educational program titled "Shared Decision Making in Lung Cancer Screening" to assist healthcare workers with identifying eligible patients for lung cancer screening and helping patients make a well-informed decision about whether to be screened.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen Lee Pearson, PA-C Po Box 468, Alcester, SD 57001-0468 Ph: (605) 934-2122 | Karen Lee Pearson, PA-C 104 West 2nd Street, Alcester, SD 57001-0468 Ph: (605) 934-2122 |
News Archive
Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Researchers at the University of Pennsylvania School of Medicine are now studying an investigational treatment that may offer a significant new, minimally-invasive option for those suffering from advanced widespread emphysema.
Compared to patients receiving care from primary care physicians, asthma patients who are under the care of an allergist report fewer asthma control problems and less sever asthma symptoms, according to new research in the December 2005 Journal of Allergy & Clinical Immunology (JACI).
The American College of Chest Physicians and Thomas Jefferson University are launching a free online educational program titled "Shared Decision Making in Lung Cancer Screening" to assist healthcare workers with identifying eligible patients for lung cancer screening and helping patients make a well-informed decision about whether to be screened.
› Verified 9 days ago